Merck KGaA CEO Karl-Ludwig Kley says following the late February announcement of the company's acquisition of biotech supplier Millipore, he was asked more than once if the $6 billion price was too high. "I have a clear answer: No, Millipore is worth every euro," he says, as quoted in BusinessWeek. He adds the takeover "will transform" Merck's life science chemicals division. Article